• #17 : Ensacove Enters the Lung Cancer Treatment Arena

  • Jan 12 2025
  • Length: 6 mins
  • Podcast

#17 : Ensacove Enters the Lung Cancer Treatment Arena

Listen for free

View show details

  • Summary

  • The FDA has approved Ensacove (ensartinib), a new second-generation ALK inhibitor, as a first-line treatment for ALK-positive non-small cell lung cancer (NSCLC) in patients who have not previously received an ALK inhibitor. Developed by a subsidiary of China's Betta Pharmaceuticals, Ensacove is the first innovative targeted lung cancer drug from a Chinese company to reach the global market. Clinical trial data from the eXalt3 study showed a 44% reduction in the risk of disease progression or death compared to Xalkori. While Ensacove is entering a market with other established ALK inhibitors, including Roche's Alecensa, which showed a 57% reduction in the risk of disease progression or death, and has also been approved for adjuvant treatment and it represents a significant new treatment option for patients.

    Hosted on Acast. See acast.com/privacy for more information.
    Show more Show less
Show more Show less

What listeners say about #17 : Ensacove Enters the Lung Cancer Treatment Arena

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available